In the management of Persistent Postural-Perceptual Dizziness (PPPD) and complex vestibular loss, gravity is not a limiter. The limitation lies in the central nervous system’s inability to accurately process gravitational and motion signals.
“When a patient develops a strong visual component or a strong somatosensory component as a maladaptive strategy, we must look at the neurochemical environment to understand why the brain has lost its sensory gating ability.”
The Neurochemistry of Balance: Understanding SSRIs vs. SNRIs
Selective Serotonin Reuptake Inhibitors (SSRIs)
Primarily target the serotonergic system to stabilize the patient’s internal alarm. In the vestibular patient, the goal is to manage the following:
Primary Neurotransmitter Goal: SSRIs block the reabsorption of serotonin to lower the ‘volume’ of the limbic system. This is crucial for patients who are in a state of constant hypervigilance, meticulously checking their balance every second.
Sensory Strategy Impact: By boosting serotonin, we reduce autonomic arousal. This dampens the emotional drive and fear-avoidant behaviors that often prevent a patient from engaging in necessary movement.
Clinical Efficacy: These agents are most effective when anxiety and the ‘fear of falling’ act as the primary barriers to recovery, allowing the patient to feel ‘safe’ enough to begin vestibular rehabilitation.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Provide a dual-action approach by increasing both serotonin and norepinephrine levels. This distinction is critical for the vestibular professional because of how it influences sensory gating:
The Norepinephrine Advantage: Norepinephrine is a major player in the brain’s ability to filter out redundant or ‘noisy’ background information. In PPPD, the brain’s filters are essentially broken, treating the movement of a ceiling fan or the pattern of a grocery store aisle as a primary threat to stability.
Sensory Strategy Impact: By increasing norepinephrine, we help the brain regain its ability to prioritize relevant vestibular signals over irrelevant visual noise. This directly addresses the sensory mismatch and the maladaptive reliance on a strong visual component.
Clinical Efficacy: SNRIs are used to optimize the signaling environment, helping the brain ignore the ‘fluff’ of environmental motion and focus on true postural cues. This facilitates the top-down executive control required for successful compensation.
Clinical Rationale and Professional Considerations
When choosing between these two classes, the clinician must evaluate the patient’s specific maladaptive sensory strategy. Each class offers unique benefits for the recovery environment:
Facilitating the Environment: These medications do not ‘fix’ a damaged peripheral nerve or restore a lost reflex. Instead, they support the central nervous system, making it more resilient and less reactive. By reducing the threat response, the patient can finally tolerate the head turns and visual desensitization exercises required in the clinic.
The Latency Gap: Vestibular professionals must manage patient expectations regarding timing. Neurochemical shifts do not happen overnight; it often takes 8 to 12 weeks for these changes to translate into improved postural stability.
Managing the Startup Period: The first 14 days of treatment can be challenging. Some patients may experience a temporary increase in head pressure or jitteriness as the brain adjusts to new levels of norepinephrine. Education is key here; if a patient is not warned about this ‘startup’ period, they may discontinue the medication before the therapeutic window even opens.
Conclusion: Preparing for Part 2
We use these tools to create a ‘quiet’ nervous system. Without this quiet, the patient remains stuck in a cycle of maladaptive sensory strategies, relying too heavily on their eyes or feet because the vestibular signal is drowned out by neural noise. In Part 2 of this series, we will dive into specific medications, dosing protocols, and strategies for managing the transition from pharmacology to active, high-intensity vestibular therapy.
References
Maywald, M., et al. (2026). Do I need to take an SSRI or SNRI for PPPD? ‘The Vertigo Doctor Podcast’. https://thevertigodoctor.com/podcast/131-ssri-snri-for-pppd/
The Vertigo Co. (2025). Understanding PPPD & Treatment Options. ‘The Vertigo Co Blog’. https://thevertigoco.com.au/blog/understanding-pppd/
Disclaimer
The information provided in this article is for educational and review purposes for vestibular professionals and is not intended as medical advice. I am not a physician. These medications should only be used under the direct supervision of a licensed medical doctor. Never start, stop, or change the dosage of any medication without first consulting your physician. Abruptly discontinuing SSRIs or SNRIs can lead to significant withdrawal symptoms and should always involve a medically supervised tapering process.
Note: No direct evidence currently exists to support these medications as a standalone ‘cure’ for vestibular hypofunction. They are used to support and optimize the environment necessary for central compensation.